Objective: To determine the impact of translocation t(1;19) in paediatric patients diagnosed with precursor B-cell acute lymphoblastic leukaemia.
Methods: The retrospective study was conducted at the Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan, and comprised data from January 2012 to January 2018 of paediatric patients diagnosed with precursor B-cell acute lymphoblastic leukaemia. Data of patients having t(1;19) translocation with or without complex karyotype formed group A, while data of patients without any cytogenetic abnormality formed the control group B. Relapse and event-free survival were calculated and the outcomes were compared between the groups. Data was analysed using SPSS 20.
Results: Of the 450 subjects whose data was analysed, 84(18.7%) were included; 25(30%) in group A and 59(70%) were in group B. There were 21(84%) males and 4(16%) females in group A with mean age on presentation 3.68±0.6 years compared to 41(69.4%) males and 18(30.5%) females with mean age on presentation 4.0±0.92 (p>0.05). There were no differences between the groups in terms of baseline markers (p>0.05). The relapse and event-free survival rates were also not significantly different between the groups (p>0.05).
Conclusion: There was no significant difference related to outcomes of precursor B-cell acute lymphoblastic leukaemia patients having t(1;19) translocation with or without complex karyotype and those without any cytogenetic abnormality, indicating that translocation t(1;19)-positive patients do not need treatment intensification.
Keywords: Acute Pre-B ALL, Children, t (1;19), Oncoprotein E2A-PBX1. (JPMA 72: 1736; 2022)
Acute lymphoblastic leukaemia (ALL) is one of the most common childhood cancers, and over the years, ALL outcomes have improved manifold due to the introduction of intensive chemotherapy regimen.1 This success has only been possible due to the better understanding of the nature of paediatric ALL and modification of therapy as per the cytogenetics. Numerous chromosomal aberrations, cytogenetic abnormalities have been identified in precursor B and T cell lymphoblastic leukaemia, that have special correlation with the clinical presentation and treatment outcomes , hence chromosomal analysis are routinely performed as cytogenetic abnormalities play an important role in risk stratification and treatment of choice.2 Precursor B-cell (Pre-B) ALL is associated with many cytogenetic abnormalities that are important prognostic factors.3 The common chromosomal translocations seen in paediatric Pre-B ALL are t(8;21) TEL-AML1, t(1;19)(q23; p13) E2A-PBX1, t(9;22) BCR-ABL, t(15;17), t(4;11) MLL-AF4.4
Translocation t(1;19) (q23; p13) is the second most commonly seen chromosomal translocation, and it fuses the gene coding the basic helix-loop-helix transcription factor TCF3 with the gene coding the homeodomain protein PBX1.5 It affects the cellular differentiation and results in malignancies.6 It was once considered a high-risk chromosomal abnormality associated with poor prognosis, but with better understanding and modification of chemotherapy protocols, it is no longer considered as one, and does not require intensified therapy.7 Fewer studies regarding cytogenetic variations have been reported from Pakistan. MS Shaikh et al. reported the incidence of translocation t (1;19) about 1.4% among children diagnosed with Pre-B ALL.8 The current study was planned to evaluate the impact of translocation t (1;19) in paediatric Pre-B ALL cases in terms of outcomes in a Pakistan population.
Materials and Methods
The retrospective study was conducted at the Shaukat Khanum Memorial Cancer Hospital and Research Centre (SKMCH&RC), Lahore, Pakistan, and comprised data from January 2012 to January 2018. SKMCH&RC is a trust organisation where oncology patients get treatment from all over Pakistan.
After exemption from the institutional ethics review board, patient data was retrieved from the institutional electronic medical records database. Total 450 patients from January 2012 to January 2018 were diagnosed with Pre-B ALL. Twenty-five patients with translocation t (1;19) and 59 patients without any translocations or abnormality were included in the study. Patients with other chromosomal translocations besides t (1;19) or abnormality and those in which cytogenetic analysis was not done were excluded from the study. Data of patients having translocation t (1:19) with or without complex karyotype formed group A, while data of patients without any cytogenetic abnormality formed the control group B.
Flowcytometry or immunohistochemistry (IHC) were used to determine the blast cells immunophenotype using either peripheral blood or bone marrow samples. Surface staining was tested with antibodies against, cluster of differentiation (CD)3, CD4, CD5, CD7, CD8, CD10, CD13, CD16, CD19, CD20, CD33, CD79a, CD11b, CD38, CD14, myeloperoxidase (MPO), terminal deoxynucleotidyl transferase (Tdt), and human leukocyte antigen-DR isotope (HLA-DR).9 At least15-20 metaphases were analysed and chromosome identification and karyotyping was based on the International System for Human Cytogenetic Nomenclature (ISCN) guidelines.10 Patients with t(1;19) (q23;p13) were classified as having balanced or unbalanced translocation.11 Since the E2A-PBX1 fusion gene is not measured at the study site, it is not a part of the current study.
The initial risk stratification of patients was based on age and white blood cell (WBC) counts as per the National Cancer Institute (NCI); age 1-10 years and WBC <50x109/L were stratified as standard risk, while age ≥10 years and WBC >50x109/L indicated high risk.12 Treatment was given as per the United Kingdom Acute Lymphoblastic leukaemia (UKALL) 2011 guidelines.13 Cytogenetics were reported 2 weeks after the initiation of induction therapy, but treatment was not intensified for patients with t(1;19). End-of-induction assessment was based on minimal residual disease (MRD) or the blast count in bone marrow where MRD was not available.
Data was analysed using SPSS20. Descriptive statistics were reported as frequencies and percentages for quantitative data, like age, WBC count at presentation, and qualitative data, like gender. Chi-square test was applied to assess the relationship between disease parameters and outcomes. Survival analysis was done using the Kaplan-Meir curve method. Event-free survival (EFS) was calculated from the date of diagnosis till death due to disease, progression of disease, relapse, and abandonment of treatment. Log-rank test was applied on the survival curves. P ≤ 0.05 was deemed significant.
Of the 450 subjects whose data was analysed, 84(18.7%) were included; 25(30%) in group A and 59(70%) were in group B. There were 21(84%) males and 4(16%) females in group A with mean age on presentation 3.68±0.6 years compared to 41(69.4%) males and 18(30.5%) females in group B with mean age on presentation 4.0±0.92 (p>0.05). There were no differences between the groups in terms of baseline markers or outcomes (p>0.05) (Table 1). Overall, 1(1.2%) patient had baseline WBC >50x 109/L.
In group A, 14(56%) cases had balanced t (1;19) translocation, while 11(44%) had unbalanced t (1;19) der (19) translocation (Table 2).
MRD, assessed at day 30, was negative in 17(%) cases in group A, whereas in 8(%) cases, bone marrow trephine examination was used to measure the disease status which was in remission. The median follow-up time was 43 months (SD±30.5) (interquartile range-(IQR)60). The 3-year EFS had no significant difference between the two groups (p>0.05) (Figure 1). Also, no significant difference was seen in EFS between cases of balanced and unbalanced translocation t (1;19) (Figure 2).
In group A, 4(16%) patients had disease relapse. Among them, 2(50%) patients had late central nervous system (CNS) relapse, and they were on treatment with relapse chemotherapy protocol, 1(25%) had a second relapse while on treatment and was offered palliation, and 1(25%) patient died secondary to sepsis. Also, 2(50%) of those patients had very early relapse, at 12 months and 7 months, respectively; 1(35%) had combined orbital and CNS relapse, and 1(25%) had bone marrow relapse. The latter 2(50%) opted for palliative treatment.
Translocation t(1;19), both balanced and unbalanced, cases are commonly seen in paediatric Pre-B ALL. The present study reported the incidence of t(1;19) of almost 25 (5.5%) (n=450) compared to 65 of 1004 patients reported in another Asian study which reported the incidence of E2A-PBX1, and it was not measured in the current study.14 A study reported the incidence of translocation t(1;19) in children aged >10 years, while the current study the age range was 2-5 years.15
Translocation t(1;19) (q23; p13) results in the chimeric protein E2A-PBX1(TCF3-PBX1) are no longer considered a prognostic factor.6 The outcomes of t(1;19) translocation used to be controversial in the past because due to less intensive chemotherapy regimen there were increased risk of relapse, especially CNS. With the introduction of intensified chemotherapy protocol, the overall survival has improved over the years.16 However limited data is available on the Pre-B ALL cytogenetics from Pakistan and data from western world cannot be generalised.
Four patients in the current study had disease relapse; 2 had isolated CNS relapse, 1 had both ocular and CNS relapse, and 1 had medullary relapse. S. Jeha et al. also reported similar results.17 Due to low number of patients with translocation t(1;19) and inability to detect TCF3-PBX1 fusion gene, the current results would be skewed. Both forms of translocation t(1;19) (q23; p13), balanced and unbalanced, were included, and EFS with unbalanced translocation was 81.8% compared to balanced translocation (64.3%) (p=0.217), Anderson et al. reported similar results.18
The critical prognostic factor in pre-B ALL is the response to therapy.19 MRD measurement at the study site was available from 2015 onwards. Before that, treatment was stratified as per bone marrow trephine results. Overall, 17 of the 25 patients with t(1;19) in whom MRD was measured at the end of induction, the value was <10-1 which is the institutional cut-off limit, suggesting that patients treated with UKALL guidelines do not need risk stratification based on t(1;19).
The SKMCH&RC has modified treatment protocol based on UKALL 2019 guidelines, but, due to limited resources and expertise, stem cell transplant (SCT) and other salvage therapies in relapsed patients are not employed.20
There was no significant difference related to outcomes of Pre-B ALL patients having t(1;19) translocation with or without complex karyotype and those without any cytogenetic abnormality, indicating that translocation t(1;19)-positive patients do not need treatment intensification.
Limitations: Patients aged 2-5 years were included. Sample size was not calculated as study was duration dependent and all patients diagnosed with translocation t (1;19) and without any chromosomal translocation were included. This can cause a decrease in the power of the study.
Acknowledgement: The authors are grateful to the patients and their families for there support.
Conflict of Interest: All the authors state that “there is no conflict of interest to declare”.
Source of Funding: None.
1. Hu YX, Lu J, He HL, Wang Y, Li JQ, Xiao PF, et al. evaluation of minimal residual disease as risk stratification for CCLG-ALL-2008 treatment protocol in pediatric B precursor acute lymphoblastic leukemia. Eur Rev Med Pharmacol Sci 2016;20:1680-90.
2. Johansson B, Mertens F, Mitelman F. Clinical and biological importance of cytogenetic abnormalities in childhood and adult acute lymphoblastic leukemia. Ann Med 2004;36:492-503. doi: 10.1080/07853890410018808.
3. Amjad A, Wali RM, Anjum S, Mansoor R. A Single Institution's Experience with Cytogenetic and MRD Outcomes in Pediatric Acute Lymphoblastic Leukemia. J Coll Physicians Surg Pak 2019;29:549-52. doi: 10.29271/jcpsp.2019.06.549.
4. Chebihi ZT, Belkhayat A, Chadli E, Hilal L, Skhoun H, Hessissen L, et al. Cytogenetic Profile of Moroccan Pediatric Acute Lymphoblastic Leukemia: Analysis of 155 Cases With a Review of the Literature. Clin Lymphoma Myeloma Leuk 2018;18:e241-8. doi: 10.1016/j.clml.2018. 04.004.
5. Hein D, Dreisig K, Izraeli S, Schmiegelow K, Borkhardt A, Fischer U. Determination of the Origin of the t (1; 19) TCF3-PBX1 Fusion By Genomic Inverse PCR for Exploration of Ligated Breakpoints (GIPFEL). Blood 2018;132:4093. Doi: 10.1182/blood-2018-99-110521
6. Malhotra P, Jain S, Agarwal A, Sharma A, Agarwal N, Kapoor G. Incidence and Prognostic Impact of TCF3-PBX1 Fusion in Childhood Acute Lymphoblastic Leukemia: A Single Centre Experience. Indian J Hematol Blood Transfus 2022;38:164-8. doi: 10.1007/s12288-021-01452-7.
7. Pang L, Liang Y, Pan J, Wang JR, Chai YH, Zhao WL. Clinical features and prognostic significance of TCF3-PBX1 fusion gene in Chinese children with acute lymphoblastic leukemia by using a modified ALL-BFM-95 protocol. Pediatr Hematol Oncol 2015;32:173-81. doi: 10.3109/08880018.2014.983625.
8. Shaikh MS, Ali SS, Khurshid M, Fadoo Z. Chromosomal abnormalities in Pakistani children with acute lymphoblastic leukemia. Asian Pac J Cancer Prev 2014;15:3907-9. doi: 10.7314/apjcp.2014.15.9.3907.
9. Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis 2014;6:e2014073. doi: 10.4084/MJHID.2014.073.
10. Simons A, Shaffer LG, Hastings RJ. Cytogenetic Nomenclature: Changes in the ISCN 2013 Compared to the 2009 Edition. Cytogenet Genome Res 2013;141:1-6. doi: 10.1159/000353118.
11. Wafa A, As'sad M, Liehr T, Aljapawe A, Al Achkar W. Childhood pre-B cell acute lymphoblastic leukemia with translocation t(1;19)(q21.1;p13.3) and two additional chromosomal aberrations involving chromosomes 1, 6, and 13: a case report. J Med Case Rep 2017;11:94. doi: 10.1186/s13256-017-1251-1.
12. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:18-24. doi: 10.1200/JCO.1918.104.22.168.
13. Khan S, Anwar S, Latif MF, Farooq A, Faizan M. Induction-remission response in peadiatric acute lymphoblastic leukaemia, Lahore protocol versus UKALL 2011 interim guidelines. J Pak Med Assoc 2020;70:591-6. doi: 10.5455/JPMA.6586.
14. Gao C, Zhao XX, Li WJ, Cui L, Zhao W, Liu SG, et al. Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients. Am J Hematol 2012;87:1022-7. doi: 10.1002/ajh.23307.
15. Uckun FM, Sensel MG, Sather HN, Gaynon PS, Arthur DC, Lange BJ, et al. Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. J Clin Oncol 1998;16:527-35. doi: 10.1200/JCO.1922.214.171.1247.
16. Chessels JM, Swansbury GJ, Reeves B, Bailey CC, Richards SM. Cytogenetics and prognosis in childhood lymphoblastic leukaemia: results of MRC UKALL X. Medical Research Council Working Party in Childhood Leukaemia. Br J Haematol 1997;99:93-100. doi: 10.1046/j.1365-2141.1997.3493163.x.
17. Jeha S, Pei D, Raimondi SC, Onciu M, Campana D, Cheng C, et al. Increased risk for CNS relapse in pre-B cell leukemia with the t(1;19)/TCF3-PBX1. Leukemia 2009;23:1406-9. doi: 10.1038/leu. 2009. 42.
18. Andersen MK, Autio K, Barbany G, Borgstrom G, Cavelier L, Golovleva I, et al. Paediatric B-cell precursor acute lymphoblastic leukaemia with t(1;19)(q23;p13): clinical and cytogenetic characteristics of 47 cases from the Nordic countries treated according to NOPHO protocols. Br J Haematol 2011;155:235-43. doi: 10.1111/j.1365- 2141.2011.08824.x.
19. Digiuseppe JA. Acute lymphoblastic leukemia: diagnosis and detection of minimal residual disease following therapy. Clin Lab Med 2007;27:533-49, vi. doi: 10.1016/j.cll.2007.05.005.
20. Pearce J, Friar S, Jigoulina G, Bate J. SARS CoV-2 Antibody Persistence During Induction Chemotherapy for Pediatric T-Cell Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol 2021;43:e1258- 9. doi: 10.1097/MPH.0000000000002182.